In a bid to reopen their economies, Italy’s 20 regions are buying hundreds of thousands of antibody tests. Amid the chaos, the world’s top test makers are battling it out for control of a new, poorly regulated market — and the U.S. could soon find itself in a similar bind.
Can The U.S. Learn From Italy, Where Antibody Test Makers Are Fighting For A New Market?
